Check-Cap Ltd. (NASDAQ: MBAI)
Answers to frequently asked questions about Check-Cap, the MBody AI merger, stock trading, and shareholder resources.
Check-Cap Ltd. is an Israeli clinical-stage medical diagnostics company that developed the C-Scan® System, an innovative ingestible capsule designed for preparation-free colorectal cancer screening. Founded with the mission of removing barriers to colorectal cancer screening, the company has been listed on NASDAQ since 2015.
In September 2025, Check-Cap announced a definitive merger agreement with MBody AI Corp., marking a strategic transformation from medical devices to embodied artificial intelligence. The company's NASDAQ ticker changed from CHEK to MBAI in December 2025 to reflect this new direction.
MBody AI is an emerging leader in embodied artificial intelligence, developing and deploying the MBody AI Orchestrator, a hardware-agnostic platform that delivers real-time data intelligence and AI-driven performance insights across robotic systems. MBody AI's technology serves industries including hospitality, healthcare, logistics, and data center operations.
The merger was approved by Check-Cap shareholders with approximately 98% of votes cast in favor. Check-Cap has submitted a NASDAQ listing application. The merger remains subject to customary closing conditions and is targeted for completion in the first half of 2026. For the latest updates, please see our Press Releases section.
Following the closing of the merger, current Check-Cap equityholders are expected to own approximately 10% of the combined company on a fully diluted basis, while MBody AI equityholders will own approximately 90%. Specific details regarding the exchange ratio and treatment of shares are described in the Proxy Statement filed with the SEC. Shareholders should review these documents carefully.
Upon completion of the merger, the combined company is expected to be renamed "MBody AI Ltd." and will continue to trade on the NASDAQ Capital Market.
Detailed information about the proposed merger is available in our SEC Filings section and on the SEC's EDGAR database at www.sec.gov. You can also visit our Press Releases section for the latest updates.
Check-Cap trades on the NASDAQ Capital Market under the ticker symbol MBAI. The Company's previous ticker symbol was CHEK.
Check-Cap ordinary shares are traded on the NASDAQ Capital Market. You can view real-time stock information on our Stock Information page.
The transfer agent for Check-Cap ordinary shares is Equiniti Trust Company, LLC, located at 6201 15th Avenue, Brooklyn, NY 11219. You can reach them toll-free at (800) 937-5449 or internationally at (718) 921-8124. Visit the Shareholder Portal for account access.
All SEC filings are available on our SEC Filings page and on the SEC's EDGAR database at www.sec.gov.
Check-Cap is classified as a Foreign Private Issuer (FPI) under SEC rules because it is incorporated in Israel. As an FPI, the Company follows a different reporting framework than domestic U.S. issuers. Check-Cap files an Annual Report on Form 20-F (instead of Form 10-K) and reports material developments and interim financial results on Form 6-K (instead of quarterly reports on Form 10-Q).
As a Foreign Private Issuer, Check-Cap is permitted to follow certain Israeli home country corporate governance practices instead of otherwise applicable NASDAQ listing requirements. The Company currently relies on home country practice exemptions with respect to director nomination procedures, approval of officer compensation, certain shareholder approval thresholds for dilutive events and acquisitions, and quorum requirements at general meetings of shareholders.
Following home country governance practices may provide less protection to investors than the NASDAQ listing requirements applicable to domestic U.S. issuers. For a full discussion of these practices and associated risks, please review our Annual Report on Form 20-F available on our SEC Filings page.
Forward-Looking Statements: This website contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934, as amended. These statements involve known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied. Forward-looking statements include, but are not limited to, statements regarding the proposed merger with MBody AI Corp., the expected timing of completion of the transaction, the combined company's anticipated operations, and the expected benefits of the transaction. These statements are subject to risks, including the ability to satisfy closing conditions, NASDAQ listing approval, regulatory approvals, and other factors described in Check-Cap's filings with the SEC, including its Annual Report on Form 20-F and the F-1 Registration Statement. The C-Scan® System is not approved in the United States and is currently an investigational device. Investors are urged to review these filings, available at the Investor Relations page, for a more complete discussion of risks and uncertainties. Check-Cap assumes no obligation to update forward-looking statements except as required by law.
Additional Information: In connection with the proposed merger, Check-Cap Ltd. has filed a Registration Statement on Form F-1 and a Proxy Statement with the SEC. Investors and security holders are urged to read these documents and any amendments or supplements thereto, as well as other relevant documents filed with the SEC, because they contain important information about the proposed transaction. These documents are available free of charge at the SEC's website at www.sec.gov and on the Company's Investor Relations page.
No Offer or Solicitation: This website does not constitute an offer to sell, a solicitation of an offer to buy, or a recommendation to purchase any securities of Check-Cap Ltd. or any other entity. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.